As per recent reports, it has been revealed that Venus Remedies has got green signal from the US Patent Office for its new drug CSE 1034, which targets drug resistant infections. The drug has been found to be quite effective in treating many infections.

Venus Medical Research Centre Vice President Mufti Suhail Sayeed was of the view, "The US patent of CSE 1034... Is a landmark development for initiating the process of commercialization of this novel drug, designed specifically to target growing bacterial resistance mechanisms”.

He further affirmed that the drug will be quite beneficial for India, which is looking for ways to treat bacterial infections. One of the best parts of the drug is that it can even curb the effect of superbug.

The company said that they have been carrying a research, which will target superbugs like carbapenemase resistant Metallobetalactamses. It has been further revealed that they have asked the regulatory authorities to speed up their tracking process for other antibiotic drugs as well.

The Infectious Diseases Society of America (IDSA) has also urged the US Food and Drug Administration (USFDA) to speed up the marketing approval process.

VMRC Joint MD Manu Chaudhary said that in order to get approval from the FDA, they have conducted clinical trials on more than 1,000 people.